Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Kicks Off Unapproved Drug Crack-Down With Carbinoxamine Enforcement

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is focusing initially on drugs containing the antihistamine carbinoxamine because of safety concerns in children.

You may also be interested in...



Low-profile Cough/Cold/Allergy Meds Target Of Latest FDA Push Against Unapproved Rx Drugs

The agency doesn't know the drugs' share of the market, but uncertainties about their safety and efficacy constitute an untenable risk for consumers, CDER compliance chief says.

Low-profile Cough/Cold/Allergy Meds Target Of Latest FDA Push Against Unapproved Rx Drugs

The agency doesn't know the drugs' share of the market, but uncertainties about their safety and efficacy constitute an untenable risk for consumers, CDER compliance chief says.

FDA Announces Withdrawal Of Unapproved Suppository Drugs For Nausea/Vomiting

Agency also is revoking NDA approval of King’s Tigan trimethobenzamide suppositories.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel